Ayanbola Elegbe

584 total citations
22 papers, 424 citations indexed

About

Ayanbola Elegbe is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Ayanbola Elegbe has authored 22 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 7 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Ayanbola Elegbe's work include Chronic Lymphocytic Leukemia Research (7 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Lymphoma Diagnosis and Treatment (4 papers). Ayanbola Elegbe is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Lymphoma Diagnosis and Treatment (4 papers). Ayanbola Elegbe collaborates with scholars based in United States, Germany and Argentina. Ayanbola Elegbe's co-authors include Michael Schiff, Michael A. Maldonado, R. Valente, Gustavo Citera, Roy Fleischmann, Michael E. Weinblatt, Désirée van der Heijde, Mark C. Genovese, Maxime Dougados and Manuela Le Bars and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

Ayanbola Elegbe

22 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ayanbola Elegbe United States 8 308 142 116 104 80 22 424
Jeffrey Box United States 3 336 1.1× 177 1.2× 137 1.2× 112 1.1× 58 0.7× 5 445
Sheila Kelly United States 11 400 1.3× 155 1.1× 220 1.9× 61 0.6× 66 0.8× 17 553
E. Keystone Canada 8 259 0.8× 108 0.8× 86 0.7× 59 0.6× 70 0.9× 26 357
Fedra Irazoque-Palazuelos Mexico 10 464 1.5× 180 1.3× 155 1.3× 115 1.1× 66 0.8× 24 539
Ravi Rao United Kingdom 5 184 0.6× 66 0.5× 109 0.9× 102 1.0× 58 0.7× 8 336
L.E. Burgers Netherlands 16 617 2.0× 202 1.4× 126 1.1× 79 0.8× 86 1.1× 23 724
George Vratsanos United States 9 519 1.7× 186 1.3× 296 2.6× 123 1.2× 123 1.5× 13 738
Riitta Koivuniemi Finland 14 260 0.8× 74 0.5× 110 0.9× 59 0.6× 45 0.6× 26 496
Eric Amante Australia 5 361 1.2× 193 1.4× 100 0.9× 113 1.1× 65 0.8× 7 417
Sabrina Rebello United States 14 403 1.3× 166 1.2× 206 1.8× 51 0.5× 40 0.5× 48 467

Countries citing papers authored by Ayanbola Elegbe

Since Specialization
Citations

This map shows the geographic impact of Ayanbola Elegbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayanbola Elegbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayanbola Elegbe more than expected).

Fields of papers citing papers by Ayanbola Elegbe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayanbola Elegbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayanbola Elegbe. The network helps show where Ayanbola Elegbe may publish in the future.

Co-authorship network of co-authors of Ayanbola Elegbe

This figure shows the co-authorship network connecting the top 25 collaborators of Ayanbola Elegbe. A scholar is included among the top collaborators of Ayanbola Elegbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayanbola Elegbe. Ayanbola Elegbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strand, Vibeke, Laure Gossec, Laura C. Coates, et al.. (2024). Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis Care & Research. 76(8). 1139–1148. 1 indexed citations
2.
Sands, B E, Axel Dignaß, Peter M. Irving, et al.. (2022). P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North. Journal of Crohn s and Colitis. 16(Supplement_1). i339–i340. 3 indexed citations
3.
Armuzzi, Alessandro, Raymond K. Cross, Gary R. Lichtenstein, et al.. (2022). DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis. Journal of Crohn s and Colitis. 16(Supplement_1). i094–i095. 9 indexed citations
4.
Long, Millie D., Gary R. Lichtenstein, Jonathan Calkwood, et al.. (2022). 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS. Gastroenterology. 162(7). S–5. 2 indexed citations
5.
Cross, Raymond K., Jonathan Calkwood, Ashwini Pai, et al.. (2021). P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. The American Journal of Gastroenterology. 116(1). S9–S10. 6 indexed citations
6.
7.
8.
Genovese, Mark C., César Pacheco‐Tena, Eduardo Mysler, et al.. (2018). Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. The Journal of Rheumatology. 45(8). 1085–1092. 21 indexed citations
9.
Jayne, David, Mary Anne Dooley, David Wofsy, et al.. (2018). LB03A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT OR PLACEBO ON STANDARD OF CARE IN PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS. Nephrology Dialysis Transplantation. 33(suppl_1). i636–i637. 1 indexed citations
10.
11.
Trachtman, Howard, Debbie S. Gipson, Michael J.G. Somers, et al.. (2017). Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. Kidney International Reports. 3(1). 115–121. 17 indexed citations
12.
13.
Schiff, Michael, Michael E. Weinblatt, R. Valente, et al.. (2013). Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the Rheumatic Diseases. 73(1). 86–94. 208 indexed citations
14.
Schiff, Michael, Michael E. Weinblatt, R. Valente, et al.. (2013). OP0044 Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the Ample Study. Annals of the Rheumatic Diseases. 72. A64–A64. 5 indexed citations
15.
Genovese, Mark C., Michael Schiff, Michael E. Luggen, et al.. (2012). Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy. The Journal of Rheumatology. 39(8). 1546–1554. 52 indexed citations
16.
17.
Genovese, M. C., G. Léon, Eduardo Mysler, et al.. (2012). FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data. Annals of the Rheumatic Diseases. 71. 378–378. 2 indexed citations
18.
Smolen, Josef S, Maxime Dougados, Corine Gaillez, et al.. (2012). AB0543 Remission using different composite disease indices in MTX-IR RA patients treated with abatacept or infliximab, +MTX. Annals of the Rheumatic Diseases. 71. 669–669. 1 indexed citations
19.
Huizinga, T., P. Emery, René Westhovens, et al.. (2011). Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept.. Data Archiving and Networked Services (DANS). 63(10). 2 indexed citations
20.
Nash, Peter, S. Nayiager, M. C. Genovese, et al.. (2011). THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA. Internal Medicine Journal. 41. 15–15. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Box Breakdown of academic impact, for papers by Sheila Kelly Breakdown of academic impact, for papers by E. Keystone Breakdown of academic impact, for papers by Fedra Irazoque-Palazuelos Breakdown of academic impact, for papers by Ravi Rao Breakdown of academic impact, for papers by L.E. Burgers Breakdown of academic impact, for papers by George Vratsanos Breakdown of academic impact, for papers by Riitta Koivuniemi Breakdown of academic impact, for papers by Eric Amante Breakdown of academic impact, for papers by Sabrina Rebello
Rankless by CCL
2026